


## Ibrutinib deacryloylpiperidine

**Cat. No.:** HY-78727  
**CAS No.:** 330786-24-8  
**Molecular Formula:** C<sub>17</sub>H<sub>13</sub>N<sub>5</sub>O  
**Molecular Weight:** 303.32  
**Target:** Btk  
**Pathway:** Protein Tyrosine Kinase/RTK  
**Storage:** 4°C, protect from light  
 \* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (82.42 mM; Need ultrasonic)					
	H <sub>2</sub> O : < 0.1 mg/mL (insoluble)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		3.2968 mL	16.4842 mL	32.9685 mL
<b>5 mM</b>			0.6594 mL	3.2968 mL	6.5937 mL	
	<b>10 mM</b>		0.3297 mL	1.6484 mL	3.2968 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (8.24 mM); Suspended solution; Need ultrasonic					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib <sup>[1]</sup> . Ibrutinib is a selective, irreversible Btk inhibitor with an IC <sub>50</sub> of 0.5 nM <sup>[2]</sup> .
--------------------	--

### REFERENCES

[1]. Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.

[2]. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA